VENBIO PARTNERS LLC
Q1 2022 Form 13-F

SAN FRANCISCO, CALIFORNIA
CIK 0001776382 · CRD 290045 · Exempt reporting adviser
$451.1M Reported Value Total
Exempt Reporting Adviser
Source: Form ADV filed 2026-03-12
Reported value
$451.1M
Quarter over quarter
-14.5%
Holdings
10
Top-10 concentration
100.0%

Key People

Named on the latest Form 13-F filing — not necessarily an owner
David Pezeshki
Chief Financial Officer

Filing Navigation

13F Metrics

Loading 13F Metrics

Q1 2022 13F record

Q1 2022 13F filing summary

Q1 2022 Form 13F portfolio summary
Period of report March 31, 2022
Filed May 16, 2022
Form 13F-HR
Reported value $451.1M
Positions 10
Change in reported value -18.7%
New positions 1
Exited positions 0
Position turnover 10.0%
Top-10 concentration 100.0%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q2 2026 13F
Filed Aug 14, 2026
7 $519.4M
Q1 2026 13F
Filed May 15, 2026
6 $280.6M
Q4 2025 13F
Filed Feb 17, 2026
6 $216.3M
Q3 2025 13F
Filed Nov 14, 2025
6 $176.4M
Q2 2025 13F
Filed Aug 14, 2025
6 $114.8M
Q1 2025 13F
Filed May 15, 2025
7 $123.6M
Q4 2024 13F
Filed Feb 14, 2025
7 $170.7M
Q3 2024 13F
Filed Nov 14, 2024
6 $194.3M
Q2 2024 13F
Filed Aug 14, 2024
6 $231.5M
Q1 2024 13F
Filed May 15, 2024
5 $281.9M
Q4 2023 13F
Filed Feb 14, 2024
7 $667.2M
Q3 2023 13F
Filed Nov 14, 2023
8 $352.7M
Q2 2023 13F
Filed Aug 14, 2023
7 $276.3M
Q1 2023 13F
Filed May 15, 2023
6 $180.4M
Q4 2022 13F
Filed Feb 14, 2023
7 $322.5M
Q3 2022 13F
Filed Nov 14, 2022
8 $432.2M
Q2 2022 13F
Filed Aug 15, 2022
9 $351.2M
Q1 2022 13F
Filed May 16, 2022
10 $451.1M
Q4 2021 13F
Filed Feb 14, 2022
9 $555.1M
Q3 2021 13F
Filed Nov 15, 2021
9 $1.0B

11 earlier quarters on file — choose one from the quarter menu above.

Top 10 holdings · Q1 2022

Largest Q1 2022 13F positions by reported value
# Holding Reported value % of portfolio
1 ALXO ALX ONCOLOGY HLDGS INC $163.9M 36.34%
2 HRMY HARMONY BIOSCIENCES HLDGS IN $75.1M 16.66%
3 VTYX VENTYX BIOSCIENCES INC $68.0M 15.08%
4 PHVS PHARVARIS N V $41.8M 9.26%
5 CINC CINCOR PHARMA INC $34.7M 7.7%
6 AKRO AKERO THERAPEUTICS INC $30.8M 6.83%
7 IMPL IMPEL NEUROPHARMA INC $17.6M 3.9%
8 CMPI CHECKMATE PHARMACEUTICALS IN $11.7M 2.6%
9 ELEV ELEVATION ONCOLOGY INC $6.6M 1.46%
10 VRNA VERONA PHARMA PLC $808.0K 0.18%

Values as reported on the Q1 2022 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings